182 related articles for article (PubMed ID: 18171726)
21. [Heart failure after acute myocardial infarct. Early aldosterone blockade increases survival rate].
MMW Fortschr Med; 2005 Jul; 147(27-28):44. PubMed ID: 16041942
[No Abstract] [Full Text] [Related]
22. [Misdiagnosed emergency: heart failure symptoms after infarct. Rapid aldosterone block can safe the tired heart].
MMW Fortschr Med; 2008 May; 150(22):48-9. PubMed ID: 18700263
[No Abstract] [Full Text] [Related]
23. Usefulness of matrix metalloproteinase-9 plasma levels to identify patients with preserved left ventricular systolic function after acute myocardial infarction who could benefit from eplerenone.
Kampourides N; Tziakas D; Chalikias G; Papazoglou D; Maltezos E; Symeonides D; Konstantinides S
Am J Cardiol; 2012 Oct; 110(8):1085-91. PubMed ID: 22742718
[TBL] [Abstract][Full Text] [Related]
24. [Selective aldosterone blocking in heart failure. Eplerenone reduces the risk after infarction].
MMW Fortschr Med; 2003 Oct; 145(44):42-3. PubMed ID: 14655506
[No Abstract] [Full Text] [Related]
25. Drug insight: aldosterone-receptor antagonists in heart failure--the journey continues.
Kalidindi SR; Tang WH; Francis GS
Nat Clin Pract Cardiovasc Med; 2007 Jul; 4(7):368-78. PubMed ID: 17589427
[TBL] [Abstract][Full Text] [Related]
26. Aldosterone antagonists: a new treatment option for patients with post-myocardial infarction heart failure.
Ajani AE; Marwick TH; Krum H
Cardiovasc Revasc Med; 2006; 7(4):234-6. PubMed ID: 17174870
[TBL] [Abstract][Full Text] [Related]
27. New therapy update. Inspra (eplerenone tablets).
Kloner RA
Congest Heart Fail; 2003; 9(6):341-2. PubMed ID: 14688507
[No Abstract] [Full Text] [Related]
28. New treatment option for heart failure patients: eplerenone.
Southworth MR; Cavallari LH
J Cardiovasc Nurs; 2004; 19(6):390-5. PubMed ID: 15529060
[TBL] [Abstract][Full Text] [Related]
29. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study.
Rossignol P; Cleland JG; Bhandari S; Tala S; Gustafsson F; Fay R; Lamiral Z; Dobre D; Pitt B; Zannad F
Circulation; 2012 Jan; 125(2):271-9. PubMed ID: 22128223
[TBL] [Abstract][Full Text] [Related]
30. [Aldosterone and aldosterone antagonists. Eplerenone in cardiac insufficiency after myocardial infarction].
Heinzl S
Med Monatsschr Pharm; 2005 Mar; 28(3):76-9. PubMed ID: 15794365
[No Abstract] [Full Text] [Related]
31. Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction.
Keating GM; Plosker GL
Drugs; 2004; 64(23):2689-707. PubMed ID: 15537370
[TBL] [Abstract][Full Text] [Related]
32. Does eplerenone have a future in the management of hypertension in Europe?
Gosse P; Macfadyen RJ
J Hum Hypertens; 2006 Nov; 20(11):829-32. PubMed ID: 16915301
[No Abstract] [Full Text] [Related]
33. [Pharmacological sheet: eplerenone (Inspra), orally].
J Pharm Belg; 2011 Sep; (3):93-4. PubMed ID: 21995102
[No Abstract] [Full Text] [Related]
34. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction.
Gheorghiade M; Khan S; Blair JE; Harinstein ME; Krum H; Mukherjee R; Pitt B;
Am Heart J; 2009 Sep; 158(3):437-43. PubMed ID: 19699868
[TBL] [Abstract][Full Text] [Related]
35. Management of heart failure and left ventricular systolic dysfunction following acute myocardial infarction.
Conti CR
Clin Cardiol; 2005 Jan; 28(1):1-2. PubMed ID: 15704523
[No Abstract] [Full Text] [Related]
36. Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure.
Iqbal J; Parviz Y; Pitt B; Newell-Price J; Al-Mohammad A; Zannad F
Eur J Heart Fail; 2014 Feb; 16(2):143-50. PubMed ID: 24464876
[TBL] [Abstract][Full Text] [Related]
37. [Efficient improvement of prognosis after myocardial infarct? Additional aldosterone inhibition is required].
MMW Fortschr Med; 2005 Dec; 147(48):66-7. PubMed ID: 16392155
[No Abstract] [Full Text] [Related]
38. [REMINDER Study: myocardial infarct without heart failure: does eplerenone have an advantage?].
Overbeck P
MMW Fortschr Med; 2013 Mar; 155 Spec No 1(1):20. PubMed ID: 24260911
[No Abstract] [Full Text] [Related]
39. The role of aldosterone receptor antagonists in the management of heart failure: an update.
Nagarajan V; Chamsi-Pasha M; Tang WH
Cleve Clin J Med; 2012 Sep; 79(9):631-9. PubMed ID: 22949344
[TBL] [Abstract][Full Text] [Related]
40. [Therapy of heart failure after myocardial infarction. With eplerenone a new course].
MMW Fortschr Med; 2004 Oct; 146(43):58-9. PubMed ID: 15559524
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
